FDA Grants Priority Review to Gedatolisib: What This Breakthrough Means for Breast Cancer Treatment

The FDA has granted priority review to gedatolisib, a first-in-class PI3K/mTOR inhibitor for HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer. In this episode, we explain why this fast-tracked review is such a major milestone—and how it could change treatment options for patients worldwide. You’ll learn: What FDA priority review means and why it matters for cancer patientsHow gedatolisib works and why it’s different from existing breast cancer therapiesWhy HR+/HER2–, PIK3CA...